Richard D Baird
Overview
Explore the profile of Richard D Baird including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
36
Citations
2196
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Coombes R, Howell S, Lord S, Kenny L, Mansi J, Mitri Z, et al.
Nat Commun
. 2025 Mar;
16(1):2242.
PMID: 40050276
No abstract available.
2.
Burdon A, Baird R, Jaki T
Stat Methods Med Res
. 2024 Oct;
33(11-12):2098-2114.
PMID: 39410878
Adaptive enrichment allows for pre-defined patient subgroups of interest to be investigated throughout the course of a clinical trial. These designs have gained attention in recent years because of their...
3.
Glaviano A, Wander S, Baird R, Yap K, Lam H, Toi M, et al.
Drug Resist Updat
. 2024 Jun;
76:101103.
PMID: 38943828
Cell cycle dysregulation is a hallmark of cancer that promotes eccessive cell division. Cyclin-dependent kinase 4 (CDK4) and cyclin-dependent kinase 6 (CDK6) are key molecules in the G1-to-S phase cell...
4.
Carmona J, Chavarria E, Donoghue K, von Gertten C, Oberrauch P, Pailler E, et al.
Cancer Discov
. 2024 Jun;
14(7):1147-1153.
PMID: 38870393
Cancer Core Europe brings together the expertise, resources, and interests of seven leading cancer institutes committed to leveraging collective innovation and collaboration in precision oncology. Through targeted efforts addressing key...
5.
Ring A, Kilburn L, Pearson A, Moretti L, Afshari-Mehr A, Wardley A, et al.
Clin Cancer Res
. 2023 Sep;
29(23):4751-4759.
PMID: 37773077
Purpose: Approximately 10% to 15% of triple-negative breast cancers (TNBC) have deleterious mutations in BRCA1 and BRCA2 and may benefit from PARP inhibitor treatment. PARP inhibitors may also increase exogenous...
6.
Glaviano A, Foo A, Lam H, Yap K, Jacot W, Jones R, et al.
Mol Cancer
. 2023 Aug;
22(1):138.
PMID: 37596643
The PI3K/AKT/mTOR (PAM) signaling pathway is a highly conserved signal transduction network in eukaryotic cells that promotes cell survival, cell growth, and cell cycle progression. Growth factor signalling to transcription...
7.
Coombes R, Howell S, Lord S, Kenny L, Mansi J, Mitri Z, et al.
Nat Commun
. 2023 Aug;
14(1):4741.
PMID: 37550302
No abstract available.
8.
Coombes R, Howell S, Lord S, Kenny L, Mansi J, Mitri Z, et al.
Nat Commun
. 2023 Jul;
14(1):4444.
PMID: 37488191
Samuraciclib is a selective oral CDK7-inhibitor. A multi-modular, open-label Phase I study to evaluate safety and tolerability of samuraciclib in patients with advanced malignancies was designed (ClinicalTrials.gov: NCT03363893). Here we...
9.
Fischer S, Gotze T, Omlin A, Baird R, Dawson K, Zitt C, et al.
JCO Precis Oncol
. 2022 Nov;
6:e2200006.
PMID: 36331248
No abstract available.
10.
Brown S, Hinsley S, Hall E, Hurt C, Baird R, Forster M, et al.
Clin Cancer Res
. 2022 May;
28(17):3639-3651.
PMID: 35552622
Radiotherapy has proven efficacy in a wide range of cancers. There is growing interest in evaluating radiotherapy-novel agent combinations and a drive to initiate this earlier in the clinical development...